TY - JOUR
T1 - Patients' expectations of benefits from large-panel genomic tumor testing in rural community oncology practices
AU - MCGI Working Group
AU - Anderson, Eric C.
AU - DiPalazzo, John
AU - Edelman, Emily
AU - Helbig, Petra
AU - Reed, Kate
AU - Miesfeldt, Susan
AU - Thomas, Christian
AU - Lucas, F. Lee
AU - Fenton, Anny T.H.R.
AU - Antov, Andrey
AU - Hall, Michael J.
AU - Roberts, J. Scott
AU - Rueter, Jens
AU - Han, Paul K.J.
AU - Erickson, Nicholette
AU - Movalia, Mayur
AU - Skacel, Marek
AU - Espinosa, Allan
AU - Gupta, Ridhi
AU - Kumar, Rachit
AU - Polkinghorn, Richard
AU - Darus, Christopher
AU - Remick, Scot
AU - Christman, Robert
AU - Rasmussen, Karen
AU - Thomas, Christian
AU - Brooks, Philip
AU - Chodkiewicz, Catherine
AU - Harb, Antoine
AU - Sinclair, Sarah
AU - Rubin, Peter
AU - Connelly, Elizabeth
AU - Georges, Peter
AU - Bourne, Jennifer
AU - Choquette, Linda
AU - Fasman, Ken
AU - Flewellen, Cristen
AU - Edelman, Emily
AU - Guerrette, Lory
AU - Helbig, Petra
AU - Mockus, Susan
AU - Reed, Kate
AU - Rueter, Jens
AU - Sanghavi, Kunal
N1 - Publisher Copyright:
© 2021 by American Society of Clinical Oncology
PY - 2021
Y1 - 2021
N2 - PURPOSE Large-panel genomic tumor testing (GTT) is an emerging technology that promises to make cancer treatment more precise. Because GTT is novel and complex, patients may have unrealistic expectations and limited knowledge of its benefits. These problems may limit the clinical value of GTT, but their prevalence and associated factors have not been explored. METHODS Patients with cancer enrolled in a large initiative to disseminate GTT in community oncology practices completed surveys assessing their expectations, knowledge, and attitudes about GTT. The study sample (N = 1, 139) consisted of patients with a range of cancer types (22% gynecologic, 14% lung, 10% colon, 10% breast, and 46% other malignancies) and cancer stages (4% stage I, 3% stage II, 15% stage III, and 74% stage IV). Mean age was 64 years (standard deviation = 11); 668 (59%) were women; 71% had no college degree; 57% came from households with less than $50,000 US dollars household income; and 73% lived in a rural area. RESULTS Generally, patients had high expectations that they would benefit from GTT (M = 2.81 on 0-4 scale) and positive attitudes toward it (M = 2.98 on 0-4 scale). Patients also had relatively poor knowledge about GTT (48% correct answers on an objective test of GTT knowledge). Greater expectations for GTT were associated with lower knowledge (b = -0.46; P,.001), more positive attitudes (b = 0.40; P,.001), and lower education (b = -0.53; P,.001). CONCLUSION This research suggests patients have high expectations that they will benefit from GTT, which is associated with low knowledge, positive attitudes, and low education. More research is needed to understand the concordance between expectations and actual clinical outcomes.
AB - PURPOSE Large-panel genomic tumor testing (GTT) is an emerging technology that promises to make cancer treatment more precise. Because GTT is novel and complex, patients may have unrealistic expectations and limited knowledge of its benefits. These problems may limit the clinical value of GTT, but their prevalence and associated factors have not been explored. METHODS Patients with cancer enrolled in a large initiative to disseminate GTT in community oncology practices completed surveys assessing their expectations, knowledge, and attitudes about GTT. The study sample (N = 1, 139) consisted of patients with a range of cancer types (22% gynecologic, 14% lung, 10% colon, 10% breast, and 46% other malignancies) and cancer stages (4% stage I, 3% stage II, 15% stage III, and 74% stage IV). Mean age was 64 years (standard deviation = 11); 668 (59%) were women; 71% had no college degree; 57% came from households with less than $50,000 US dollars household income; and 73% lived in a rural area. RESULTS Generally, patients had high expectations that they would benefit from GTT (M = 2.81 on 0-4 scale) and positive attitudes toward it (M = 2.98 on 0-4 scale). Patients also had relatively poor knowledge about GTT (48% correct answers on an objective test of GTT knowledge). Greater expectations for GTT were associated with lower knowledge (b = -0.46; P,.001), more positive attitudes (b = 0.40; P,.001), and lower education (b = -0.53; P,.001). CONCLUSION This research suggests patients have high expectations that they will benefit from GTT, which is associated with low knowledge, positive attitudes, and low education. More research is needed to understand the concordance between expectations and actual clinical outcomes.
KW - Aged
KW - Female
KW - Health Knowledge, Attitudes, Practice
KW - Humans
KW - Male
KW - Medical Oncology/methods
KW - Middle Aged
KW - Neoplasms/diagnosis
KW - Patients/psychology
KW - Rural Population/statistics & numerical data
KW - Surveys and Questionnaires
UR - http://www.scopus.com/inward/record.url?scp=85119169470&partnerID=8YFLogxK
U2 - 10.1200/PO.21.00235
DO - 10.1200/PO.21.00235
M3 - Article
C2 - 34632254
AN - SCOPUS:85119169470
SN - 2473-4284
VL - 5
SP - 1554
EP - 1562
JO - JCO Precision Oncology
JF - JCO Precision Oncology
IS - 5
ER -